Assay News and Research

RSS

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

Elan's first-quarter total revenue up by 27% to $310.5M

Elan Corporation, plc, today reported its first quarter 2010 financial results.

21 Apr 2010

ForteBio introduces new Octet QK(e) instrumentation system

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.

20 Apr 2010

AMRI extends and expands research collaboration with CHDI Foundation

AMRI announced today the five year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc. (CHDI), focused on the discovery of new therapeutic agents for the treatment of Huntington's disease (HD).

20 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Affymetrix, Inc. today announced the launch of the Affymetrix® MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples. With the MIP Copy Number Service, scientists can now obtain high-quality allele-specific copy number data from FFPE samples. The service is available for research use only exclusively through the Affymetrix® Research Services Laboratory (ARSL).

20 Apr 2010

Artificial human skin with dermis made from fibrin-agarose biomaterial

Scientists from the University of Granada, Spain, have generated artificial human skin by tissular engineering basing on agarose-fibrin biomaterial. The artificial skin was grafted onto mice, and optimal development, maturation and functionality results were obtained. This pioneering finding will allow the clinical use of human skin and its use in many laboratory tests on biological tissues -which, additionally, would avoid the use of laboratory animals.

20 Apr 2010

Gamma-prime fibrinogen test can help better predict people at risk for heart attack

A simple blood test can identify people who are at risk for a heart attack, including thousands who don't have high cholesterol, according to researchers at Oregon Health & Science University.

20 Apr 2010

S1P5 may serve as future strategy in biotherapy for esophageal cancer: Study

Esophageal cancer is one of the most common malignancies worldwide. Its mortality is very high due to relatively late diagnosis and inefficient treatment. The ability to reverse the outcome of esophageal cancer is limited due to a poor understanding of its biology. Progression of esophageal cancer may be associated with sphingosine 1-phosphate and its receptors S1P1-5, which play an important role in other cancers.

20 Apr 2010

NanoString Technologies launches new miRNA assay kits

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced a unique new product for miRNA analysis that includes a multiplexed assay for profiling the human miRNA transcriptome in a single tube. The company introduced the new assay kit, which expands the applications for its nCounter® Analysis System, at the American Association for Cancer Research annual meeting.

From NanoString Technologies 20 Apr 2010

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

NewLink Genetics Corporation announced today data from a Phase 1/2 study showing that patients with progressive advanced non-small cell lung cancer treated with its HyperAcute®-Lung cancer immunotherapy experienced favorable median survival. The data were presented at the 101st American Association for Cancer Research (AACR) Annual Meeting.

20 Apr 2010

ITI granted AOAC approval for additional Salmonella matrices

Idaho Technology, Inc. (ITI) has received AOAC Performance Tested Method approval for two additional Salmonella matrices—stainless steel environmental samples and dry pet food. These matrices join the list of already approved matrices in the Salmonella LT Food Security System including chocolate, cooked ham, fresh raw chicken, lettuce, raw ground beef, and liquid whole eggs. This assay uses real-time PCR technology to identify the presence of Salmonella in less than one hour after a pre-enrichment period.

20 Apr 2010

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.

19 Apr 2010

TGen, Asuragen sign microRNA technology agreement for pancreatic cancer research

The Translational Genomics Research Institute and Asuragen Inc. today announced a research agreement that could lead to ways of detecting cancer before it spreads.

17 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.

16 Apr 2010

New findings may allow clinicians to prevent complications in pregnancy

Researchers at Mount Sinai School of Medicine have found that epigenetic marks on human placentas change from the first trimester of pregnancy to the third, a discovery that may allow clinicians to prevent complications in pregnancy.

15 Apr 2010

AMRI announces multi-year research agreement with Navigen Pharmaceuticals

AMRI announced today that it has initiated a research collaboration with Navigen Pharmaceuticals, Inc. focused on the development of new drug therapies.

15 Apr 2010

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Building upon its powerful BD™ LSR cell analyzer platform, BD Biosciences launched today a new off-the-shelf BD LSRFortessa™ System, which uses up to four lasers -- blue, red, violet and UV -- that enable the detection of up to 18 colors simultaneously.

15 Apr 2010

Assay News and Research

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

Elan's first-quarter total revenue up by 27% to $310.5M

ForteBio introduces new Octet QK(e) instrumentation system

AMRI extends and expands research collaboration with CHDI Foundation

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Artificial human skin with dermis made from fibrin-agarose biomaterial

Gamma-prime fibrinogen test can help better predict people at risk for heart attack

S1P5 may serve as future strategy in biotherapy for esophageal cancer: Study

NanoString Technologies launches new miRNA assay kits

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

ITI granted AOAC approval for additional Salmonella matrices

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

TGen, Asuragen sign microRNA technology agreement for pancreatic cancer research

Serametrix announces commercial launch of serum test for measuring serum antibodies

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

New findings may allow clinicians to prevent complications in pregnancy

AMRI announces multi-year research agreement with Navigen Pharmaceuticals

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

One Health, One Mission: The World Organisation for Animal Health on the AMR Frontline

Uniting Against Resistance: The World Health Organization for World Antimicrobial Awareness Week 2023

Tackling Antimicrobial Resistance: A Conversation with Dr. Beverley Isherwood

Latest News